Posted by Michael Wonder on 22 Dec 2022
ICER publishes final evidence report on gene therapies for haemophilia A and B
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix at approximately $2.9 million.
The ICER today released a Final Evidence Report assessing the comparative clinical effectiveness and value of etranacogene dezaparvovec (Hemgenix, CSL Behring) for haemophilia B. ICER also updated the previous haemophilia A assessment on valoctocogene roxaparvovec (Roctavian, BioMarin).
